- Home
- ESRT vs FTRE Comparison
ESRT vs FTRE Comparison
Compare ESRT & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- FTRE
- Stock Information
- Founded
- ESRT 2011
- FTRE 1996
- Country
- ESRT United States
- FTRE United States
- Employees
- ESRT N/A
- FTRE N/A
- Industry
- ESRT Real Estate Investment Trusts
- FTRE Medical Specialities
- Sector
- ESRT Real Estate
- FTRE Health Care
- Exchange
- ESRT Nasdaq
- FTRE Nasdaq
- Market Cap
- ESRT 1.7B
- FTRE 1.9B
- IPO Year
- ESRT 2013
- FTRE N/A
- Fundamental
- Price
- ESRT $9.62
- FTRE $17.69
- Analyst Decision
- ESRT Hold
- FTRE Hold
- Analyst Count
- ESRT 2
- FTRE 11
- Target Price
- ESRT $11.50
- FTRE $23.30
- AVG Volume (30 Days)
- ESRT 1.1M
- FTRE 923.7K
- Earning Date
- ESRT 02-18-2025
- FTRE 03-10-2025
- Dividend Yield
- ESRT 1.46%
- FTRE N/A
- EPS Growth
- ESRT N/A
- FTRE N/A
- EPS
- ESRT 0.27
- FTRE N/A
- Revenue
- ESRT $758,432,000.00
- FTRE $2,975,600,000.00
- Revenue This Year
- ESRT N/A
- FTRE N/A
- Revenue Next Year
- ESRT $1.85
- FTRE $1.09
- P/E Ratio
- ESRT $35.17
- FTRE N/A
- Revenue Growth
- ESRT 4.19
- FTRE 2.80
- 52 Week Low
- ESRT $8.78
- FTRE $16.53
- 52 Week High
- ESRT $11.62
- FTRE $41.02
- Technical
- Relative Strength Index (RSI)
- ESRT 33.84
- FTRE 39.63
- Support Level
- ESRT $9.28
- FTRE $16.94
- Resistance Level
- ESRT $9.85
- FTRE $18.52
- Average True Range (ATR)
- ESRT 0.22
- FTRE 0.98
- MACD
- ESRT -0.03
- FTRE -0.10
- Stochastic Oscillator
- ESRT 29.57
- FTRE 22.59
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.